Results 191 to 200 of about 28,958 (244)

Dabigatran Etexilate

Drugs, 2008
Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced platelet aggregation. Dabigatran etexilate pharmacokinetics were linear across a wide dosage range.
Mark, Sanford, Greg L, Plosker
openaire   +2 more sources

Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation

Annals of Internal Medicine, 2020
BACKGROUND It is unclear whether anticoagulant type is associated with the risk for osteoporotic fracture, a deleterious complication of anticoagulants among patients with atrial fibrillation (AF).
W. Lau, C. Cheung, Kenneth K C Man, E. Chan, C. Sing, G. Lip, C. Siu, J. Lam, A. Lee, I. Wong   +9 more
semanticscholar   +1 more source

Dabigatran as an oral anticoagulant in patients with Budd–Chiari syndrome post‐percutaneous endovascular intervention

Journal of Gastroenterology and Hepatology, 2020
Anticoagulants play an important role in the management of Budd–Chiari syndrome. There is a paucity of data on the efficacy and safety of direct‐acting oral anticoagulants—dabigatran, among patients with Budd–Chiari syndrome.
Sanchit Sharma, Ramesh Kumar, Gyanranjan Rout, S. Gamanagatti, R. Shalimar   +4 more
semanticscholar   +1 more source

Use of dabigatran with antiretrovirals

HIV Medicine, 2019
ObjectivesTheoretical and untested interactions between antiretrovirals and direct‐acting oral anticoagulants have limited the use of this new class of anticoagulant in people with HIV infection. This case series, the first of its kind, reports on the successful concurrent use of the direct‐acting oral anticoagulant dabigatran and antiretroviral ...
J Perram, E O'Dwyer, C Holloway
openaire   +2 more sources

Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease

Drug Metabolism and Personalized Therapy, 2020
Background Despite the well-studied safety profile of dabigatran, its interactions with genetic polymorphism parameters are poorly understood, especially in patients with moderate chronic kidney disease (CKD).
D. Sychev, A. Skripka, Kristina Ryzhikova, P. Bochkov, R. Shevchenko, P. Krupenin, D. Ivashchenko, V. Kogay, A. Listratov, A. Krainyaya, O. Gurinovich, A. Sokolova, D. Napalkov, V. Fomin   +13 more
semanticscholar   +1 more source

Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding

Circulation, 2019
Background: Although dabigatran has a favorable risk-benefit profile compared with vitamin K antagonist therapy for venous thromboembolism and nonvalvular atrial fibrillation, major bleeding events, including gastrointestinal (GI) bleeding, may occur ...
Sake Van Der Wall, F A Klok
exaly   +2 more sources

Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke

Stroke, 2020
Supplemental Digital Content is available in the text. Background and Purpose— Reversal of dabigatran before intravenous thrombolysis in patients with acute ischemic stroke has been well described using alteplase but experience with intravenous ...
James Beharry, M. Waters, R. Drew, J. Fink, D. Wilson, B. Campbell, M. Parsons, T. Kleinig, Teddy Y. Wu   +8 more
semanticscholar   +1 more source

Gastrointestinal disorders and dabigatran

Scandinavian Journal of Gastroenterology, 2012
Anticoagulants play an important role in the prevention and treatment of a variety of acute and chronic thromboembolic disorders such as primary prevention and treatment of venous thromboembolism or prevention of stroke and systemic embolism in atrial fibrillation just to name of few.
Arthur, Hoffman, P R, Galle
openaire   +2 more sources

Dabigatran: A Primer for Neurosurgeons

World Neurosurgery, 2013
This study sought to present an overview of dabigatran, a new anticoagulant, and to discuss the implications for the perioperative management of patients taking dabigatran.We reviewed the English literature pertaining to the new oral anticoagulant, dabigatran (Pradaxa).Dabigatran has the advantage of providing rapid and steady anticoagulation without ...
Jennifer E, Fugate, Alejandro A, Rabinstein, Robert D, McBane, Giuseppe, Lanzino   +3 more
openaire   +2 more sources

Real-time detection and differentiation of direct oral anticoagulants (rivaroxaban and dabigatran) using modified thromboelastometric reagents.

Thrombosis Research, 2020
INTRODUCTION Timely measurement of direct oral anticoagulants (DOACs) is challenging, though clinically important. We tested the hypotheses, that thromboelastometry is able to detect dabigatran and rivaroxaban and discriminates between dabigatran and ...
S. Schäfer, Tobias Wiederkehr, T. Kammerer, Alice-Christin Acevedo, Katharina Feil, Lars Kellert, Klaus Görlinger, Ludwig C Hinske, P. Groene   +8 more
semanticscholar   +1 more source